---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076612"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:45:31.904468+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Definium Therapeutics FY2025 cash $411.6M; Phase 3 MDD trial fully enrolled, topline late Q2 2026

## Summary
- Cash, cash equivalents and investments of $411.6M as of Dec 31, 2025, up from $273.7M in 2024; expected to fund operations into 2028.
- Phase 3 MDD trial Emerge fully enrolled (149 patients); topline data anticipated late 2Q 2026.
- Phase 3 GAD trial Voyage ~80% enrolled, no sample size increase needed; topline early 3Q 2026.
- Phase 3 GAD trial Panorama enrollment on track; topline 2H 2026. Sample size re-estimation update on April 22 Investor Day.
- Completed $259M equity financing in Q4 2025; appointed new CFO, CCO, and board member Roger Adsett.

## SEC filing metadata
- accession: 0001193125-26-076612
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076612/0001193125-26-076612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076612/dftx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076612
- JSON: https://secwatch.observer/filing/0001193125-26-076612.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076612.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.